CEREDA, VITTORE
 Distribuzione geografica
Continente #
NA - Nord America 3.132
EU - Europa 169
AS - Asia 126
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 3.429
Nazione #
US - Stati Uniti d'America 3.132
SG - Singapore 72
UA - Ucraina 43
CN - Cina 33
DE - Germania 24
IE - Irlanda 24
IT - Italia 20
RU - Federazione Russa 12
GB - Regno Unito 11
FR - Francia 10
PL - Polonia 10
FI - Finlandia 9
KR - Corea 9
JP - Giappone 6
SE - Svezia 3
ID - Indonesia 2
NL - Olanda 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
AU - Australia 1
EU - Europa 1
TR - Turchia 1
Totale 3.429
Città #
Woodbridge 1.005
Houston 826
Wilmington 715
Fairfield 104
Singapore 66
Ann Arbor 49
Ashburn 48
Chandler 48
Seattle 45
Jacksonville 43
Cambridge 29
Dublin 24
Medford 21
Engelhard 16
Dearborn 15
Santa Clara 12
Kraków 10
Lawrence 9
Hangzhou 6
Rome 6
Beijing 4
Fremont 4
Hefei 4
Kunming 4
San Diego 4
Boston 3
Detroit 3
London 3
Menlo Park 3
Moscow 3
Zhengzhou 3
Brescia 2
Chongqing 2
Falls Church 2
Hanoi 2
Jinan 2
Milan 2
Norwalk 2
Palo Alto 2
Amsterdam 1
Boardman 1
Chiswick 1
Corleone 1
Guangzhou 1
Hounslow 1
Jakarta 1
Lishui 1
Monte Vista 1
Nanchang 1
Nanjing 1
Novokuznetsk 1
Nuremberg 1
Omaha 1
Paris 1
Southend 1
Southwark 1
Surabaya 1
Sydney 1
Tokyo 1
University Park 1
Venezia 1
Verona 1
Vienna 1
Wenzhou 1
Yoyogi-sanyacho,Tokyo 1
Totale 3.177
Nome #
Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer 423
Effects of conventional therapeutic interventions on the number and function of regulatory T cells 422
Immune reaction and colorectal cancer: friends or foes? 420
Venous thromboembolism risk prediction in ambulatory cancer patients: Clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio 413
The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy 365
Kallikrein-related peptidases targeted therapies in prostate cancer: Perspectives and challenges 360
Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients 354
Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches 340
Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B) 338
Issues and promises of bevacizumab in prostate cancer treatment 34
Totale 3.469
Categoria #
all - tutte 6.784
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.784


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020557 0 0 0 0 76 98 83 69 68 54 47 62
2020/2021471 46 64 44 64 55 49 59 47 13 7 21 2
2021/202278 5 7 3 1 2 8 5 3 5 9 7 23
2022/2023133 11 7 8 12 25 32 6 7 18 0 3 4
2023/202462 13 6 1 0 6 1 28 2 0 0 0 5
2024/2025116 11 64 33 8 0 0 0 0 0 0 0 0
Totale 3.469